login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

First successful below-the-knee procedures with the Proteus device performed in the USA


Friday, 13 Jul 2012 13:47
Proteus
Proteus

Angioslide, a provider of embolic capture angioplasty solutions, has announced the successful deployment of a 3X100mm Proteus device for treating peripheral artery disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, USA. Accommodating a 0.014” guide-wire, the new device allows physician to perform a PTA revascularisation in BTK vessels while capturing and removing embolic particles. 


“With Proteus having been successfully used to treat lesions in the SFA (superficial femoral artery), I had the opportunity to deploy the device in BTK procedures,” said Prakash Makam, Community Hospital. “It is an effective, easy to use tool that provides an alternative for removal of embolic material, including micro particles, that could compromise downstream vasculature flow and perfusion to the foot. This is especially important when treating high-risk, diabetic and critical limb ischaemia patients.”

Angioslide’s proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention. Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity. When retrieved through the sheath, Proteus removes the captured material from the body.


“We are excited to provide a solution for capture and removal of embolic debris for below-the-knee intervention, where the clinical consequences of emboli are amplified by small vessel diameter,” said Lihu Avitov, CEO, Angioslide. “The current set of tools available on the market for BTK intervention are suboptimal, and we look forward to meeting this important clinical need. With the successful completion of our first cases in the USA, we will introduce our product to a wider number of centers.”


According to a company release, the Proteus is the first device of its kind to receive FDA clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE mark approval for lower limb use and is being marketed in selected regions in Europe.




Add New Comment

Related Items


Most popular


One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms
Wednesday, 29 Apr 2015
Results from the 12-month data of the randomised controlled IMPROVE trial show that an endovascular strategy is cost-effective when compared to open repair in the treatment of ruptured abdominal ... One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms

 Yasuaki Arai gets standing ovation after ECIO Honorary Lecture
Friday, 24 Apr 2015
Yasuaki Arai, director of the National Cancer Center Hospital, Tokyo, Japan, and current president of the Japanese Society of Interventional Radiology (JSIR), delivered the Honorary Lecture at the E...  Yasuaki Arai gets standing ovation after ECIO Honorary Lecture

Transradial access “safe and well-tolerated” in typical IR patient population
Tuesday, 24 Mar 2015
A single-centre review of the safety and feasibility of using the transradial approach for peripheral and visceral interventions after the first 1,000 procedures finds that this access has extremely ... Transradial access “safe and well-tolerated” in typical IR patient population

Features


The challenges of measuring response in interventional oncology
Monday, 30 Mar 2015
An overview of three treatments: ablation, chemoembolization and selective interval radiation therapy, should clarify the challenges of determining tumour response in interventional oncology, write M... The challenges of measuring response in interventional oncology

Revolutionary focused ultrasound still needs to address limitations
Monday, 30 Mar 2015
Alessandro Napoli writes that therapeutic ultrasound still has some technological hurdles that need to be overcome, despite his success with the treatment over the past five years. Revolutionary focused ultrasound still needs to address limitations

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions